Study of TTX-MC138 in Subjects With Advanced Solid Tumors

NCT06260774 | Active Not Recruiting Phase 1 DMC FDA Drug

• 2 other identifiers: TTX-MC138-0021R44CA295173-01
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 4

Brief Summary

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors

Conditions

Advanced Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Dose Escalation - Adverse Events

  The safety and tolerability of escalating dose levels of TTX-MC138 to determine incidence of treatment-emergent adverse events (TEAEs).

  Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year

• Dose Escalation - Overall Response Rate (ORR)

  proportion of subjects with a best response of CR, PR, or stable disease for at least 8 weeks per RECIST version 1.1.

  Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year

Study Arms (3)

Dose level 1

EXPERIMENTAL

0.4 mg/kg of TTX-MC138

Drug: TTX-MC138

Dose level 2

EXPERIMENTAL

0.8 mg/kg of TTX-MC138

Drug: TTX-MC138

Dose level 3

EXPERIMENTAL

3.2 mg/kg of TTX-MC138

Drug: TTX-MC138

Interventions

TTX-MC138 DRUG

The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.

Dose level 1; Dose level 2; Dose level 3

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have histologically or cytologically confirmed diagnosis of relapsed/refractory metastatic or locally advanced solid tumor where no standard therapy exists, standard therapy has failed and have no available therapies with known clinical benefit.
• Must have measurable or evaluable disease per RECIST version 1.1.
• ≥18 years at the time of informed consent.
• Life expectancy of ≥3 months
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2.
• Have adequate organ function defined as:
• Platelet count ≥75×109/L with no platelet transfusions in the past 7 days
• Absolute neutrophil count ≥1.0×109/L
• Hemoglobin ≥8 g/dL (red blood cell transfusion may be used to reach 8 g/dL but must have been administered at least 1 week prior to the administration of the study drug)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \<2.5× the upper limit of normal (ULN) if no hepatic metastases are present; \<5× ULN if hepatic metastases are present
• Total bilirubin \<1.5× ULN; \<3 X ULN in the presence of Gilbert's disease
• Estimated (Cockcroft-Gault formula) or measured creatinine clearance ≥60 mL/min
• International normalized ratio (INR) ≤1.5× ULN unless participant is receiving anticoagulant therapy as long as the prothrombin time (PT) or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants
• If female of childbearing potential, either abstain from sexual intercourse or employ highly effective contraception measures during the study and for ≥30 days after the administration of the study drug. Highly effective measures include 2 forms of contraception. Postmenopausal or surgically sterile women (ie, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) are eligible. Postmenopausal status is defined as either: amenorrheic for ≥12 months following cessation of exogenous hormonal treatments and without an alternative medical cause; luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for women \<50 years of age; radiation-induced ovarian ablation with last menses ≥1 year ago; or chemotherapy-induced menopause with a ≥1-year interval since last menses. Female subjects must refrain from donating or banking eggs (ova, oocytes) and retrieving eggs for use during study treatment and for 30 days after the administration of the study drug.
• For male subjects not surgically sterile, must either abstain from sexual intercourse or employ highly effective contraception (condoms or other barrier forms of contraception) during the study and for at least 30 days after the administration of the study drug. Male subjects should also avoid semen donation or providing semen for in vitro fertilization during the above-mentioned duration.

You may not qualify if:

• Unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, or other study procedures and study restrictions.
• Have received anticancer therapy (including both systemic therapy and radiotherapy, but not including immunotherapy or other antibody therapies) within 14 days or 5 half-lives (whichever is shorter) of study drug administration or;
• a. received antibody therapy within 30 days before the start of study drug administration.
• Have a history of a second primary malignancy that has been diagnosed or required active therapy within the past year.
• Have central nervous system (CNS) metastases or primary CNS tumor that is associated with progressive neurologic symptoms or requires ongoing corticosteroids to control the CNS disease. Subjects must have a stable neurologic status without steroid support for ≥2 weeks before the start of study drug administration. Subjects with stable or asymptomatic CNS metastases or primary CNS are eligible.
• Require treatment with traditional/herbal medicines or their preparations indicated for tumors or with adjuvant anti-tumor effects that cannot be discontinued during the study.
• Have clinically significant, uncontrolled cardiovascular disease including congestive heart failure Class III or Class IV according to the New York Heart Association classification; myocardial infarction or unstable angina within the previous 6 months; uncontrolled hypertension (Grade ≥3); or clinically significant, uncontrolled arrhythmia, including bradyarrhythmia that may cause QT prolongation (eg, Type II second-degree heart block or third-degree heart block).
• Have QT interval corrected using Fridericia's formula \>480 msec. Unless the subject has a history of prolonged QT syndrome or torsade de pointes or a familial history of prolonged QT syndrome.
• Have a history of acute ischemic stroke, diagnosed by imaging (CT or MRI) or clinical diagnosis within 6 months prior to screening.
• Have any severe or uncontrolled systemic disease or condition per clinical judgement, including: (i) uncontrolled hypertension or diabetes; (ii) serious cardiac, pulmonary, or renal conditions; (iii) active bleeding diatheses; (iv) any active type of bacterial, viral, fungal, or other infection that would pose a significant risk to the subject in the opinion of the Investigator; (v) cerebrovascular accident within the last 6 months before administration of study drug.
• Have received a major surgical procedure within 28 days before the start of study drug administration (procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures). The study center should discuss other minor surgeries with the sponsor.
• Clinical diagnosis of hemochromatosis or secondary iron overload,
• Documented detectable HIV RNA within 4 weeks of study drug administration,
• Acquired immunodeficiency syndrome defining opportunistic infections within the past 12 months prior to study enrollment, and
• Is not on antiretroviral therapy for at least 4 weeks prior to study enrollment.

Sponsors & Collaborators

• TransCode Therapeutics: lead

Study Sites (4)

Mary Crowley Cancer Center

Dallas, Texas, 75230, United States

Location

MD Anderson Cancer Center

Houston, Texas, 77230, United States

Location

START Mountain Region

West Valley City, Utah, 84119, United States

Location

Next Oncology

Fairfax, Virginia, 22031, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Dose Escalation Study Design

Study Record Dates

• First Submitted: December 12, 2023
• First Posted: February 15, 2024
• Study Start: September 5, 2024
• Primary Completion: September 30, 2025
• Study Completion (Estimated): February 1, 2027
• Last Updated: October 2, 2025

Record last verified: 2025-10

Locations

US (4)